Michael Grissinger appointed as new Chairman of AnaCardio

Stockholm, Sweden, June 3, 2024 

AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board.

Michael has had a long and successful career in the pharmaceutical industry, leading large value business  development transactions across multiple therapeutic areas and products. Michael spent more than two  decades at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical  Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and  

M&A. Since his retirement in 2018, Michael has served on the boards of several public biotechnology  companies. He holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox  School of Business. 

Michael Grissinger commented: “AnaCardio, with its promising novel concept to treat heart failure, is an  exciting Swedish company with potential to address a significant unmet patient need. I am looking forward to being a part of the journey forward.” 

Mark Quick, board member, Partner at Flerie and outgoing chairman commented: “We are delighted to  welcome Michael to the board as the new chairman. With his long tenure and track record in business  development and M&A at leading pharma companies, he brings the exact credentials required to continue building the AnaCardio success story.” 

About AnaCardio 

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel  drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska  Institutet showing improved contractility of the heart muscle through a unique and differentiated  mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule, which is being  developed as a contractile agent in heart failure patients.  

You can find more information about AnaCardio at www.anacardio.com.  

For further information, please contact 

Patrik Strömberg, CEO 

Telephone: +46 704 156 159 

E-mail: Patrik.stromberg@anacardio.com

Share this article on social media

Rekommenderade artiklar